Dr. Oz faces scrutiny over potential conflicts of interest as Medicare chief nominee

Dr. Mehmet Oz, nominated by Donald Trump to lead the Centers for Medicaid and Medicare, has raised concerns about potential conflicts of interest. A recent social media post suggests he may continue promoting health products while in office. Oz's post highlighted adaptogens like ashwagandha from iHerb, where he serves as a global adviser and is a shareholder. Critics question how he will manage his financial ties to health companies as he prepares for his new role. Medical experts have previously criticized Oz for endorsing unproven treatments and supplements. His past promotion of hydroxychloroquine during the pandemic, despite lacking evidence, has also drawn scrutiny due to his financial interests in a related company.